Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Phase II study of mitoxantrone hydrochloride liposome injection in unresectable locally advanced or metastatic urothelial carcinoma
CTR20211302Phase 2Active
- Sponsor
- CSPC ZhongQi Pharmaceutical Technology
- Start
- Nov 2021
- Modality
- DNA Intercalators/Alkylators → Nucleic Acid-Directed Small Molecules → Small Molecules
- Countries
- 1
01
Overview
A Phase 2 trial of mitoxantrone in transitional cell carcinoma (TCC), sponsored by CSPC ZhongQi Pharmaceutical Technology. Started Nov 2021; status: active.
02
Drugs
mitoxantrone
03
Conditions
transitional cell carcinoma (TCC)
Beyond the preview
Go deeper on CTR20211302.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on CTR20211302.